


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 30, 2008.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121  
Patent Application  
Docket No. ARS-106

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Bruce D. Hissong, Ph.D.  
Art Unit : 1646  
Applicants : Amanda Proudfoot, Marie Kosco-Vilbois  
Serial No. : 10/517,726  
Filed : December 10, 2004  
Conf. No. : 6045  
For : Novel Antagonists of CXCR3-Binding CXC Chemokines

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated March 31, 2008 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 37-42), with traverse. As the antagonist, Applicants hereby elect mutants of CXCL11.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: